Open AccessNeoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
Author(s) -
Ute Warnecke-Eberz,
Patrick Sven Plum,
Viola Schweinsberg,
Uta Drebber,
Christiane Bruns,
Dolores T. Müller,
A. H. Hölscher,
Elfriede Bollschweiler
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i23.3236
Subject(s) - podoplanin , medicine , neoadjuvant therapy , immunohistochemistry , esophageal cancer , esophagus , esophagectomy , oncology , adenocarcinoma , cancer , pathology , breast cancer
Locally advanced adenocarcinoma of the esophagus (EAC) and squamous cell carcinoma (ESCC) result in a worse prognosis. Neoadjuvant treatment improves survival, however, only for responders. The transmembrane glycoprotein podoplanin is overexpressed in squamous cell carcinomas, miRNA-363 is associated to its regulation in head and neck cancer.